Rustam, Tajikistan

【Patient profile】 Rustam, 61 years old, partner of a trading company in Dushanbe, Tajikistan, with a long history of smoking.

【Predicaments before coming to China】

The patient was diagnosed with non-small cell lung cancer (adenocarcinoma, stage IIIA) in the middle lobe of the right lung, with mediastinal lymph node metastasis. Tajikistan only offers traditional chemotherapy regimens; there is no mature gene testing system or targeted precision treatment. Treatment in Turkey is estimated to cost over US$55,000, with a long waiting period and low efficiency.

【The decision-making process of choosing Trisana Medguide】

According to the Dushanbe Chinese Enterprises Chamber of Commerce, Trisana Medguide completed the following within 4 days:

- Russian/Tajik medical record translation, digital scanning of pathology slides

- Remote MDT (Multidisciplinary Team) Initial Screening Consultation by Oncology Experts at Shanghai Pulmonary Hospital

- Personalized genetic testing plans, precision treatment pathways, and comprehensive cost estimates

【A complete record of my medical treatment in China】

| Timeline | Service Content |

| Day 1 | Arrive in Shanghai, private airport pick-up and check-in to exclusive partner apartment |

| Day 2 | Expert consultation, completion of baseline physical examination, NGS large panel gene sampling, PET-CT precise staging, and clarification of mediastinal lymph node metastasis status.

| Day 3 | Expedited green channel within the hospital, preliminary results of gene testing issued: EGFR 19 exon deletion mutation

| Day 4 | | Multidisciplinary team (MDT) consultation to customize an individualized, low-toxicity radical treatment plan: Initiation of oral treatment with the third-generation EGFR-targeted drug amitinib, simultaneously performing high-precision stereotactic body radiotherapy (SBRT) on mediastinal metastases.

| Day 5-10 | Completed full-course precision radiotherapy; targeted concurrent therapy was well tolerated with no severe adverse reactions.

| Day 11 | Interim follow-up assessment: The primary tumor shrank significantly by 30%, the metabolic activity of the mediastinal lymph nodes decreased significantly, and the downstaging effect was clear.

| Day 12-14 | Improve the long-term targeted maintenance therapy plan and issue a Russian-language guide for home medication, follow-up examinations, and adverse reaction management.

| Day 15 | Compliant return to Tarim with sufficient targeted drugs, signing a contract for lifetime remote follow-up service to ensure continuous cross-border treatment

【Result comparison】

| Comparison Items | Türkiye Solution | Trisana MedguidePrecision Medicine Solution for China |

| Testing & Drugs | Genetic testing outsourcing, poor accessibility of targeted drugs | Third-generation EGFR targeted drugs are available in China at significantly lower costs than similar drugs in Europe and the United States |

|Treatment Mode| Conventional radiotherapy and chemotherapy with significant toxic side effects | Targeted therapy combined with stereotactic body radiotherapy (SBRT) with individualized treatment plans, low toxicity and high efficacy|

【Customer testimonials (anonymous quote)】

"In Dushanbe, I was told that I could only receive traditional chemotherapy. Trisana Medguide allowed me to use the latest international precision targeted therapy, and the radiotherapy had almost no side effects. When I returned to China for a follow-up examination, the local doctors could hardly believe how well it worked."